12:00 AM
Feb 27, 2012
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Mitsubishi Tanabe Pharma, Novartis preclinical data

Researchers at the ALS Therapy Development Institute reported data from a mouse model of ALS showing that Gilenya significantly and dose-dependently reduced circulating levels of CD4 and CD8 lymphocytes from baseline to day...

Read the full 161 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >